Kevin Volpp of the Perelman School of Medicine and the Wharton School comments on Abilify MyCite, the first drug with an embedded sensor to track patients taking their medication, being approved by the Food and Drug Administration.

November 14, 2017 ・ From Philadelphia Inquirer